Next, to study the impact of hENT1 and hCNT3 on DZNep-mediated cytotoxicity in pancreatic cancer cells, we examined the proliferation of MIA PaCa-2 in the presence of a pharmacological inhibitor of hENT1 (10 nM NBMPR) or excess uridine (200 μM) which competitively inhibits all ENTs and CNTs. This evidence concerns the gene SLC29A1 and familial pancreatic carcinoma.